Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Urges Stockholders to Vote FOR All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial ...

Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Highlights Record Financial and Operational Results, Balanced Capital Allocation ...

The company's flagship product is called HEPLISAV-B and was fully approved as a hepatitis B vaccine in 2020. The product was clearly superior to existing standard of care Entergis-B from GSK plc ...

BVNKF now expects margin improvements from rabies/TBE vaccine production transfers to Denmark, starting in 2025. Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved ...

It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. Receive News ...

Overseen by a Board with the right skills and relevant industry experience, the Company is consistently delivering record financial and operational results. The Dynavax Board has been programmatically ...

Overseen by a Board with the right skills and relevant industry experience, the Company is consistently delivering record financial and operational results. The Dynavax Board has been ...

The company’s HEPLISAV-B® vaccine has achieved a leading 44% market share in the U.S. adult Hepatitis B market, contributing to $268 million in revenues for 2024. Dynavax anticipates continued success ...